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Abstract
IMPORTANCE—Cardiovascular risk assessment is a fundamental component of prevention of 
cardiovascular disease (CVD). However, commonly used prediction models have been formulated 
in primarily or exclusively white populations. Whether risk assessment in black adults is dissimilar 
to that in white adults is uncertain.
OBJECTIVES—To develop and validate risk prediction models for CVD incidence in black 
adults, incorporating standard risk factors, biomarkers, and subclinical disease.
DESIGN, SETTING, AND PARTICIPANTS—The Jackson Heart Study (JHS), a longitudinal 
community-based study of 5301 black adults in Jackson, Mississippi. Inclusive study dates were 
the date of a participant’s first visit (September 2000 to March 2004) to December 31, 2011. The 
median (75th percentile) follow-up was 9.1 (9.7) years. The dates of the analysis were August 
2013 to May 2015. Measurements included standard risk factors, including age, sex, body mass 
index, systolic and diastolic blood pressure, ratio of fasting total cholesterol to high-density 
lipoprotein cholesterol, estimated glomerular filtration rate, antihypertensive therapy, diabetes 
mellitus, and smoking; blood biomarkers; and subclinical disease measures, including ankle-
brachial index, carotid intimal-medial thickness, and echocardiographic left ventricular 
hypertrophy and systolic dysfunction.
MAIN OUTCOMES AND MEASURES—Incident CVD event was defined as the first 
occurrence of myocardial infarction, coronary heart disease death, congestive heart failure, stroke, 
incident angina, or intermittent claudication. Model performance was compared with the 
American College of Cardiology/American Heart Association (ACC/AHA) CVD risk algorithm 
and the Framingham Risk Score (FHS) refitted to the JHS data and evaluated in the 
Atherosclerosis Risk in Communities (ARIC) and Multi-Ethnic Study of Atherosclerosis cohorts.
RESULTS—The study cohort comprised 3689 participants with mean (SD) age at baseline was 
53 (11) years, and 64.8% (n = 2390) were female. Over a median of 9.1 years, 270 participants 
(166 women) experienced a first CVD event. A simple combination of standard CVD risk factors, 
B-type natriuretic peptide, and ankle-brachial index (model 6) yielded modest improvement over a 
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model without B-type natriuretic peptide and ankle-brachial index (C statistic, 0.79; 95% CI, 
0.75–0.83 [relative integrated discrimination improvement, 0.22; 95% CI, 0.15–0.30]). However, 
the reclassification improvement was not substantially different between model 6 and the 
ACC/AHA CVD Pooled Cohort risk equations or between model 6 and the FHS. The models 
discriminated reasonably well in the ARIC and Multi-Ethnic Study of Atherosclerosis data (C 
statistic range, 0.70–0.77).
CONCLUSIONS AND RELEVANCE—Our findings using the JHS data in the present study are 
valuable because they confirm that current FHS and ACC/AHA risk algorithms work well in black 
individuals and are not easily improved on. A unique risk calculator for black adults may not be 
necessary.
Compared with non-Hispanic white adults, black adults have a higher risk of myocardial 
infarction1 and congestive heart failure (CHF)2,3 and a 2-fold greater risk of stroke1 and 
peripheral arterial disease (PAD). Therefore, prediction and prevention of cardiovascular 
disease (CVD) in black adults is a public health priority.
One fundamental gap of knowledge in the medical literature is the paucity of data on the 
summated risk of all CVD events in black adults, rather than just of individual CVD 
components, such as coronary heart disease (CHD), PAD, or CHF.4–10 Data are limited 
regarding risk prediction models in black adults that focus on all CVD (general CVD risk 
prediction), analogous to similar algorithms available in white adults, such as in the 
Framingham Heart Study (FHS).11,12
Our major hypothesis in the present investigation was that novel biomarkers and subclinical 
disease measures offer incremental predictive usefulness over standard CVD risk factors for 
predicting CVD risk in black adults. We also posited that a parsimonious combination of 
risk factors, a few novel biomarkers, and select subclinical disease measures will offer an 
efficient approach to CVD risk prediction in this group. We tested these hypotheses in the 
community-based Jackson Heart Study (JHS). In addition, we compared the best prediction 
models with the performance of the 2013 American College of Cardiology/American Heart 
Association (ACC/AHA) CVD Pooled Cohort risk equations.13
Methods
Study Sample
The study sample consisted of participants in the JHS14 who attended their first examination 
cycle between September 2000 and March 2004. Race/ethnicity in the JHS was determined 
by self-report and confirmed using the Household Enumeration Form. The JHS recruited 
5301 self-identified black adults from the tricounty area (Hinds, Rankin, and Madison 
counties) that includes the city of Jackson, Mississippi. Approximately 30% were surviving 
members of the JHS cohort of the Atherosclerosis Risk in Communities (ARIC) study.15
For the present investigation, participants were eligible if they attended examination 1 and 
had available data on key covariates considered for prediction models (Figure 1). Written 
informed consent was obtained from all study participants, and the research protocol was 
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approved by the institutional review board of the University of Mississippi Medical Center 
for the JHS.
Standard Risk Factors
For the present investigation, we evaluated the following standard CVD risk factors reported 
in the literature to be associated with CVD risk in black adults: age, sex, body mass index, 
systolic blood pressure (BP), antihypertensive therapy, diabetes mellitus status (yes or no), 
ratio of fasting total cholesterol to high-density lipoprotein cholesterol, current smoking 
status (yes or no), and estimated glomerular filtration rate (calculated using the Chronic 
Kidney Disease Epidemiology Collaboration equations16).
Blood Biomarkers
In the investigation, the following circulating biomarkers representing distinctive biological 
pathways and that were available at the first examination in the JHS were considered: 
adiposity (adiponectin and leptin), neurohormonal activation (aldosterone, B-type natriuretic 
peptide [BNP], and cortisol), inflammation (high-sensitivity C-reactive protein [hs-CRP]), 
endothelial function (endothelin and homocysteine), glycemic control (glycated 
hemoglobin), and insulin resistance (the homeostasis model assessment of insulin resistance 
[HOMA-IR]). Most of these biomarkers have been reported to be associated with CVD 
either individually or as part of a multimarker risk score.17–19
Plasma aldosterone was measured by radioimmunoassay (intra-assay coefficient of variation 
for high and low concentrations, 8.7% and 6.2%, respectively). Circulating BNP and cortisol 
levels were measured by chemiluminescent immunoassay performed on an immunoassay 
system (ADVIA Centaur; Siemens) (intra-assay coefficient of variation, 4.2%, 3.1%, and 
3.4% for 3 BNP concentrations, respectively, and 9.1% and 7.7% for high and low cortisol 
concentrations, respectively). The hs-CRP was measured by the latex particle 
immunoturbidimetric assay (ITA; Roche Diagnostics) (intra-assay coefficient of variation,
4.5%). Enzyme-linked immunosorbent assay methods were used to measure endothelin 
(intra-assay coefficient of variation range, 9.3%–19.1%). Insulin resistance was calculated 
using the following formula for HOMA-IR: HOMA-IR (Mass Units) = Fasting Plasma 
Insulin (Microunits per Liter) × [Fasting Plasma Glucose (Millimoles per Liter)/22.5]. 
Homocysteine was measured by the fluorescence polarization immunoassay (IMx; Abbott) 
(intra-assay coefficient of variation, 4.6%, 3.2%, and 2.1%, respectively, for 3 homocysteine 
concentrations). Leptin levels were measured by radioimmunoassay using the double-
antibody/polyethylene glycol technique (Human Leptin RIA; EMD Millipore) (intra-assay 
coefficient of variation, 10%).
Subclinical Disease Variables
Ankle-Brachial Index—To determine the ankle-brachial index (ABI), systolic BP 
measurements were obtained at the ankle on each lower extremity twice. The systolic BP 
was also measured twice in the brachial artery on the right arm. Two ABIs (one for the right 
and one for the left lower extremity) were calculated as the mean of the 2 measurements of 
ankle systolic BP divided by the mean of the brachial BP readings obtained twice. The lower 
of the 2 ABIs was considered the ABI for the participant. Those with an ankle systolic BP 
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exceeding 75 mm Hg above the brachial systolic BP were excluded to avoid falsely elevated 
ABIs due to noncompressibility.20
Carotid Intimal-Medial Thickness—To determine the carotid intimal-medial thickness 
(CIMT), 3 segments of the carotid artery were imaged bilaterally using a 7.5-MHz 
transducer on an ultrasound machine(SONOS4500; Hewlett Packard). The CIMT was 
defined as the mean of the far wall IMT measurements of the common carotid, bifurcation 
carotid, and internal carotid bilaterally. Participants whose summary measures were in the 
upper pooled 10th percentile of CIMT were compared with participants whose summary 
measures were below the upper pooled 10th percentile.
Echocardiographic Variables—Echocardiograms were performed using a 2.5-MHz 
transducer mounted on the ultrasound machine. A single cardiologist with level III training 
in echocardiography (T.E.S.) read all studies. Comparisons of the readings were performed 
by a local expert (P.R.L.) and an outside expert reader. The correlation coefficient between 
readers was 0.70 for left ventricular mass (LVM).
For the present study, LVM was calculated using the American Society of Echocardiography 
corrected formula by Devereux et al.21 The LVM was indexed to height in meters to the 
exponential of 2.7 (LVM index [LVMI]) to adjust for body habitus.22 The LV ejection 
fraction was determined by visual estimation. The LV hypertrophy was defined as an LVMI 
of at least 51g/m to the exponential of 2.7 in women and men.22 The LV systolic dysfunction 
was defined as an estimated LV ejection fraction of less than 50%.23
Cardiovascular Events
For the present investigation, the incidence of a CVD event was defined as the first 
occurrence of any of 4 major CVD outcomes (myocardial infarction, fatal CHD, CHF, and 
stroke) or any of the 2 nonmajor outcomes (incident angina or intermittent claudication) 
between the date of a participant’s first visit and December 31, 2011, in the JHS.24 Incident 
MI, fatal CHD, CHF, and stroke were determined through adjudication on review of relevant 
medical records. Annual follow-up records on Rose angina and intermittent claudication 
questionnaires were used to determine the incidence of these events.24
Design and Statistical Analysis
Multivariable Cox Proportional Hazards Models and Selection of Important 
Predictors From Candidate Variables From Different Data Tiers—The approach to 
the analysis and validation for the prediction model was based on guidelines described in the 
Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or 
Diagnosis (TRIPOD) statement.25 In this investigation, each checklist item of the TRIPOD 
statement was addressed, allowing for assessment of bias and clinical relevance of the 
prediction model.
Variables were tested and then removed from the models using a variable selection 
procedure. After variable selection, we tested for time-dependent covariates among 
predictors that were selected (retained). We used Cox proportional hazards regressions26 to 
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assess the association of risk factors with the incidence of the CVD event over a median 
follow-up period of 9.1 years. We performed feature selection using a stepwise sequence27 
that combines stepwise selection and the Akaike information criterion to select the most 
parsimonious model using various combinations of risk factors (Figure 1). In model 1, we 
assessed the association of standard risk factors (ie, age, sex, systolic and diastolic BP, use of 
antihypertensive medications, ratio of fasting total cholesterol to high-density lipoprotein 
(HDL) cholesterol and fasting triglycerides, estimated glomerular filtration rate, current 
smoking, and diabetes mellitus) with incident CVD. The candidate variables in model 2 
included all standard risk factors and a panel of 10 biomarkers from various pathways, 
including adiposity (adiponectin and leptin), endothelial function (endothelin and 
homocysteine), inflammation (hs-CRP), insulin resistance (HOMA-IR and glycated 
hemoglobin), and neurohormonal activation (aldosterone, BNP, and cortisol). The candidate 
variables in model 3 and model 4 included standard risk factors and measures of subclinical 
disease (ABI, LV hypertrophy, LV systolic dysfunction, and CIMT). Specifically, candidate 
variables for model 3 included all subclinical measures for model 3 and included ABI only 
for model 4. We evaluated 2 additional models that included standard risk factors, 
biomarkers, and measures of subclinical disease. Candidate variables for model 5 consisted 
of standard risk factors, biomarkers, and all subclinical disease. Candidate variables for 
model 6 included standard risk factors, variables, BNP, and ABI based on the ease and 
practicality of obtaining these variables in primary care settings. All continuous variables 
and biomarkers were natural logarithmically transformed and then standardized within sex 
to account for their skewed distributions and sex-specific differences.
The performance of all models was evaluated using the C statistic by Harrell et al28 and the 
integrated discrimination improvement (IDI) was proposed.29 Relative IDI quantifies the 
separation between estimated risks of disease for cases vs controls after the addition of a 
biomarker or a measure of subclinical disease. The models with superior discriminative 
ability from among those not including echocardiographic traits were selected for 
comparison with the Framingham Risk Score (FRS)30 and the ACC/AHA CVD Pooled 
Cohort risk equations.13 Following recent recommendations, we refitted the FRS and 
ACC/AHA models to the JHS sample to obtain conservative estimates of their ability to 
move CVD prediction upward or downward across clinically meaningful boundaries (10-
year event rate, 7.5%) using the Net Reclassification Improvement (NRI).31 We used the 
FRS model for all CVD, which included the outcomes of CHF, fatal MI, stroke, angina, and 
claudication (similar to the outcomes used in the present model). The age limits for the 
comparison with the FRS model were between 30 and 74 years. Comparison with the 
ACC/AHA CVD Pooled Cohort risk equations involved a subsample of participants 40 to 79 
years old who were not receiving statin therapy and who were evaluated for incident major 
outcomes only (including fatal MI and stroke but excluding angina, claudication, and 
CHF).32 The NRI quantifies the increase in predicted risk categories for events and the 
decrease in risk categories for nonevents with the addition of a new marker. Therefore, the 
NRI helps identify patients who may benefit from more intensive preventive measures and 
helps identify those for whom pharmacotherapy could potentially be deferred.32
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Assessment of Prediction Model Validity—We assessed the validity of the selected 
prediction models through external validation using 2 independent black adult data sets from 
the ARIC study (n = 825), excluding overlapping participants from the JHS and the Multi-
Ethnic Study of Atherosclerosis (MESA) (n = 1564). The data sets from these 2 cohorts 
included the same sets of covariates as the prediction models we evaluated in the JHS, with 
the notable exception of the use of N-terminal pro-BNP (instead of BNP) in the ARIC study 
and the MESA. To minimize differences in distributions of the variables, all continuous 
variables were natural logarithmically transformed and standardized within sex (as in the 
JHS). Categorical traits were coded as in the JHS model development sample. Detailed 
descriptions of the ARIC study and the MESA cohorts used are provided in the eAppendix 
in the Supplement. Fixed regression coefficients associated with selected prediction models 
in the JHS (eTable 1 in the Supplement) were transported and applied to the validation 
samples, applying the same inclusion and exclusion criteria. The external validity of the 
predictions was quantified by performance related to discrimination and calibration.
Discrimination was evaluated by the C statistic by Harrell et al.28 Calibration was assessed 
using a calibration plot comparing the predicted probabilities (obtained using fixed 
regression coefficients of the prediction models) with the observed probabilities in the ARIC 
study and the MESA according to the Harrell regression modeling strategy (R package, 
version 3.2.2; R Foundation for Statistical Computing). The Green-wood-Nam-D’Agostino 
statistic was used in the evaluation of goodness of fit.33
Results
Study Sample
Table 1 summarizes the sex-specific and sex-pooled clinical and biochemical characteristics 
of the study sample. The mean (SD) age at baseline was 53 (11) years, and 64.8% (2390 of 
3689) of the participants were female. Men had higher mean values (or percentages for 
categorical factors) for all standard risk factors, with the exception of age and diabetes 
mellitus status. Biomarker distributions (median and 25th and 75th percentiles) and 
proportions of participants with prevalent subclinical disease are also summarized in Table 
1.
During a follow-up period of up to 10 years (median [75th percentile], 9.1 [9.7] years), 270 
participants (166 women) experienced a first CVD event (Figure 1). The mean sex-specific 
and sex-pooled CVD event rates are listed in Table 1. The event rates and corresponding 
total person-years for individual CVD subtypes are summarized in eTable 2 in the 
Supplement. eTable 3 in the Supplement lists the CVD outcomes (aggregate and 
disaggregated) for each of the categorical factors included in the models. Briefly, the 
numbers and event rates of individual CV subtypes were as follows: incident MI and fatal 
CHD (92 participants [2.7; 95% CI, 2.2–3.3 events per 1000 person-years]), CHF (104 
participants [3.1; 95% CI, 2.5–3.7 events per 1000 person-years]), and stroke (75 
participants [2.2; 95% CI, 1.8–2.8 events per 1000 person-years).
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Sample Sizes and Exclusion Criteria for Models Evaluated
Models considered included those (1) using standard risk factors (model 1) (n = 3689), (2) 
combining standard risk factors and blood biomarkers (n = 2802), (3) combining standard 
risk factors and measures of subclinical disease (n = 2265), and (4) combining all 3 
(standard risk factors, blood biomarkers, and subclinical disease) (n = 1745). In addition, we 
considered a model using ABI only (n = 3322) for the subclinical disease option because 
that model would be easy to implement in primary care settings (no sophisticated imaging 
would be needed). We also considered a second model using ABI as the subclinical disease 
measure and blood BNP alone for the biomarker option (n = 2672) because of a greater 
feasibility of such testing in community-based clinic settings.
For the model incorporating standard CVD risk factors, 1612 participants were excluded as 
follows (in hierarchical order): those with age outside the age range of 30 to 74 years (n = 
343), those with prevalent CVD (n = 551), those with serum creatinine level exceeding 2 
mg/dL (n = 25) (to convert creatinine level to micromoles per liter, multiply by 88.4), and 
those with missing covariates (n = 663). A total of 3689 participants were eligible for this 
analysis. The demographic profile for the study sample was similar to that of those excluded 
because of missing individual covariates.
After excluding participants with missing biomarker data, 2802 individuals were eligible for 
analyses of biomarkers. Excluded (in hierarchical order) were individuals with missing data 
for adiponectin (n = 24), aldosterone (n = 3), BNP (or those with BNP level exceeding 100 
pg/mL) (n = 745) (to convert BNP level to nanograms per liter, multiply by 1.0), glycated 
hemoglobin (n = 47), or leptin (n = 8) levels, in addition to exclusion criteria in tier 1. 
Excluded participants had significantly higher mean biomarker levels except for aldosterone, 
HOMA-IR, hs-CRP, and leptin concentrations (eTable 4 in the Supplement).
A total of 2265 individuals were retained after excluding participants with missing standard 
risk factors and data on subclinical disease, including (in hierarchical order) LVMI (n = 
1219), LV ejection fraction (n = 13), CIMT (n = 31), and ABI (n = 161). As summarized in 
eTable 4 in the Supplement, participants with missing echocardiographic data were 
significantly older and hypertensive, had a higher percentage of current smokers, and had 
higher BNP levels.
Parsimonious Models According to Data Tiers
Parsimonious models from the analysis of the different tiers of variables are summarized in 
Table 2. Specifically, the estimated multivariable-adjusted hazard ratios and their associated 
95% CIs for factors retained in the models are presented.
The standard CVD risk factors retained in model 1 included age, male sex, systolic BP, 
antihypertensive therapy, ratio of fasting total cholesterol to HDL cholesterol, estimated 
glomerular filtration rate, type 2 diabetes mellitus status, and smoking status. Triglyceride 
levels and diastolic BP were among the variables from model 1 that were dropped from this 
model based on statistical significance (P > .05).
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The factors retained in model 2 (standard risk factors and biomarkers) included all standard 
risk factors and the following blood biomarkers: BNP (P < .001), HOMA-IR (P = .009), 
adiponectin (P = .002), and glycated hemoglobin (P = .05). The corresponding 
multivariable-adjusted hazard ratios and 95% CIs are summarized in Table 2.
In model 3 (standard risk factors and subclinical disease), CIMT was the only subclinical 
disease measure that was not retained in the model. All the other subclinical diseases, LV 
systolic dysfunction (P < .001), LV hypertrophy (P = .001), and ABI (P = .005) were 
retained in the final prediction model.
On combining predictors selected among standard risk factors, blood biomarkers, and 
subclinical disease (model 5), the following variables were retained in the final prediction 
model: age, ratio of fasting total cholesterol to HDL cholesterol, smoking status, BNP, LV 
ejection fraction, LV hypertrophy, and ABI (top half of Table 2). Also summarized in the top 
half of Table 2 are the multivariable-adjusted results for (1) model 4 (which included an 
analysis of standard risk factors and ABI only and (2) model 6 (which included an analysis 
of standard risk factors, BNP, and ABI).
Discrimination and Reclassification Performance
Discrimination results for all models are summarized in the bottom half of Table 2. For 
model 1, the C statistic was 0.77 (95% CI, 0.74–0.81), and the relative IDI was 0.35 (95% 
CI, 0.16–0.57). Compared with model 3 (with a C statistic of 0.83 [95% CI, 0.78–0.88]), it is 
apparent that model 3 has better predictive value. On the other hand, the relative IDI 
suggests an increase by 0.35 times in the difference in predicted probabilities of events vs 
nonevents between model 3 and model 1. Of the models not including echocardiographic 
traits, model 6 (which included BNP and ABI, in addition to clinical risk factors) was the 
best model fit. For model 6, the C statistic was 0.79 (95% CI, 0.75–0.83), and the relative 
IDI was 0.22 (95% CI, 0.15–0.30). As a result of the models, as well as their being readily 
available in the clinical setting, we chose model 1and model 6 for reclassification 
assessment purposes and for external validation. Application of model 1 and model 6 to 
disaggregated events is summarized in eTable 5 in the Supplement.
Comparing the NRI of Selected Models With the Framingham and ACC/AHA 
Risk Scores—The C statistics for the FRS and the ACC/AHA CVD Pooled Cohort risk 
equations were 0.77 (95% CI, 0.73–0.81) and 0.75 (95% CI, 0.71–0.79), respectively. 
Compared with the FRS, model 1 reclassified 5 participants from a low-risk to high-risk 
category, but compared with ACC/AHA, only 2 participants were reclassified (Table 3). In a 
similar comparison, model 1 reclassified 67 participants to a low-risk from a high-risk 
category among participants without events compared with the FRS and 20 participants 
when compared with ACC/AHA. Therefore, the CVD event NRIs for model 1 were 0.005, 
0.019, and 0.016 when compared with model 6, the FRS, and the ACC/AHA CVD Pooled 
Cohort risk equations, respectively. The corresponding nonevent NRIs were 0.054, 0.020, 
and 0.007 compared with the same models, respectively. This conservative assessment 
comparing model 1 with refitted FRS and ACC/AHA models suggests no substantial 
improvement in reclassification. Compared with model 1, the FRS, and the ACC/AHA CVD 
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Pooled Cohort risk equations, among CVD events, model 6 moved 1, 3, and 0 participants 
from the low-risk category to the high-risk category, respectively. Among participants 
without events, model 6 moved 134, 190, and 49 participants downward to the low-risk 
category compared with model 1, the FRS, and the ACC/AHA CVD Pooled Cohort risk 
equations, respectively. Therefore, model 6 resulted in event NRIs of −0.005, 0.016, and 
0.000 and nonevent NRIs of 0.054, 0.076, and 0.024, respectively. These results further 
suggest no substantial improvement in reclassification by model 1 or model 6 compared with 
the FRS and ACC/AHA prediction models.
External Validation of the Prediction Model—Although model 3 and model 5 
generated the highest C statistics, we chose to use model 1 and model 6 for validation 
because of their ease of use in a resource-sparse setting. As noted above, the ARIC-only 
(excluding the JHS-ARIC overlap) and MESA black adults were used for validation. Sample 
characteristics for the participants in the ARIC study and MESA cohorts are summarized in 
eTable 6 in the Supplement, and the results of external validation for discrimination and 
calibration are shown in Figure 2. The C statistics for model 1 and model 6 applied to the 
ARIC study were 0.76 (95% CI, 0.69–0.82) and 0.77 (95% CI, 0.71–0.84), respectively. The 
corresponding C statistics applied to the MESA were 0.70 (95% CI, 0.66–0.75) and 0.73 
(95% CI, 0.68–0.78), respectively. The models appeared to perform better when applied to 
the ARIC study than when applied to the MESA sample in terms of discrimination, but the 
reverse was true in terms of calibration. Calibration in the large for model 1 and model 6 in 
the ARIC study (Figure 2A) and in the MESA (Figure 2B) showed poor calibration of the 
models developed in the JHS. The intercepts for both models were comparable across 
validation samples, but the slope for model 6 in the MESA was higher (mean [SD], 0.50 
[0.08]) than that in the ARIC study (mean [SD], 0.05 [0.10]), suggesting that the model from 
derivation samples predicted more CVD events than were observed in both external 
validation samples. In the MESA, there appeared to be some underestimation at low event 
rates and some overestimation at high event rates when the predicted rates were compared 
with the observed event rates.
Discussion
We evaluated a hierarchy of CVD risk prediction algorithms in black adults that start with 
standard CVD risk factors and expand to incorporate novel biomarkers and then subclinical 
disease measures. We observed important associations of specific biomarkers (which 
constitute evidence for activation of key biological pathways involved in CVD) and select 
subclinical disease measures with CVD incidence in black adults. The 2 selected models for 
comparison with current global CVD risk prediction models were model 1 (standard risk 
factor model) and model 6 that incorporated standard risk factors, blood BNP, and ABI. 
Model 6 yielded superior predictive performance compared with a model without BNP and 
ABI. However, there was no substantial improvement in reclassification compared with the 
FRS and the recently introduced ACC/AHA CVD Pooled Cohort risk equations (in a 
subsample of participants 40–79 years old not receiving statin therapy, looking at major 
outcomes only, excluding CHF).
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The performance of the 2 selected models was validated using 2 independent population-
based samples of black adults. Both models exhibited acceptable discrimination in these 
external cohorts. Based on our results, these selected models that are readily available in the 
primary care setting are likely generalizable to other black populations originating from 
different geographical regions within the United States.
Biomarkers added minimal incremental improvement in discrimination beyond model 1. 
Framingham Heart Study34 investigators studied how 10 biomarkers (hs-CRP, BNP, atrial 
natriuretic peptide, aldosterone, renin, fibrinogen, D-dimer, plasminogen activator inhibitor 
type 1, homocysteine, and the ratio of urinary albumin to creatinine) predict cardiovascular 
events and death. Similar to our study, these biomarkers provided modest incremental 
predictive information over standard risk factors in that cohort.34 In the present investigation 
after incorporating standard, subclinical, and risk factors, BNP was the only biomarker 
retained in the prediction model. The strong predictive usefulness of BNP for CVD 
incidence is most likely because of several factors, including the use of CHF in the definition 
of CVD outcomes. In addition, the natriuretic peptide system has a multifaceted role in 
cardiovascular physiology, which includes salt and water handling,35 BP homeostasis, 
cardiac and vascular structure and function,36 and inhibition of the renin-angiotensin-
aldosterone system.37 The natriuretic peptide system also influences lipid and glucose 
metabolism and homeostasis, further potentially contributing to the prognostic value of 
BNP.38–41
Furthermore, our investigation showed that adding subclinical disease measures (both ABI 
alone or the combination of ABI with echocardiographic LV mass and LV ejection fraction) 
enhanced the predictive usefulness of model 1. Lower ABI may be associated with CVD 
through its association with PAD and intermittent claudication, and it is equally plausible 
that a low ABI also is a marker of a greater burden of atherosclerotic disease in multiple 
vascular territories.42,43 It is well established that LV hypertrophy and systolic dysfunction 
are predictive of CVD.44–46 Cardiac remodeling is a result of biomechanical stressors and 
the activation of biological pathways affecting myocyte hypertrophy and function.47 In LV 
hypertrophy, the resultant supply-demand mismatch of myocardial oxygen results in a 
greater potential for myocardial ischemic events (angina and infarction).47 Finally, structural 
and functional LV remodeling can predispose affected individuals to acute decompensated 
heart failure and arrhythmic death.46,48,49
There are established prediction models developed and validated in various population-based 
cohorts for specific cardiovascular outcomes.6–8 Investigators in the FHS, Cardiovascular 
Health Study, and ARIC study have each developed risk prediction models for CHD.6,7 
Specifically, the FRS for CHD performs well in white adults and black adults in different 
settings and in other racial/ethnic groups if recalibrated for different baseline incidences of 
CHD. The FHS, ARIC study, and Cardiovascular Health Study have also developed and 
validated stroke prediction models.4,5,9 The Health ABC Study50 and the ARIC study10 have 
developed HF prediction scores using common clinical variables to predict incident HF risk. 
The ARIC study model included middle-aged white adults and black adults, whereas in the 
Health ABC Study the cohort tested was elderly, and more than 40% of participants were 
black. The benefit of model 1 in our investigation is that it predicts general CVD risk in a 
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population-based cohort of black adults, allowing for a summated risk across all CVD 
components. Establishing such a risk prediction model in black adults that focuses on all 
CVD events may allow for the formulation of prevention strategies that may contribute to 
lowering the burden of disease in this group and address the disparities in morbidity and 
mortality in this vulnerable segment of the US population. Application of the present model 
was not studied in this investigation. Instead, we focused on model development and 
validation.
Our study had some limitations. We developed prediction models in a community-based 
sample of black adults in Jackson, Mississippi. Model 3 and model 5, which both included 
echocardiographic variables, yielded the highest C statistics. However, because of the greater 
ease of use in a resource-constrained environment, we chose model 1and model 6 for 
validation. One limitation of this investigation is that the validation cohorts were small, with 
few events. In addition, external validation of our model was conducted in a subset of black 
adults in the ARIC study and compared with the ACC/AHA CVD Pooled Cohort risk 
equations, which was derived in part using data from black and white adults in the ARIC 
study. There were high rates of medication use in the MESA cohort, and it is unclear to what 
extent this factor may affect our validation results with that cohort. Because models 
contained more than 10 variables, this factor may lead to overfitting of the validation 
cohorts. Further complicating the validation analysis, BNP was used in modeling the JHS 
sample; however, BNP was not available in either the MESA or the ARIC study. N-terminal 
pro-BNP was used in place of BNP for the validation of the 2 external cohorts, which may 
also affect the validation cohorts. Another limitation is that we did not evaluate the 
predictive usefulness of coronary calcification (as a subclinical disease measure) because it 
was not available contemporaneously with our variables at JHS examination 1. Finally, 
additional investigation is warranted to identify the comparative accuracy of CVD prediction 
models incorporating standard risk factors, blood biomarkers, and measures of subclinical 
disease in other races/ethnicities. With more complex models, there was significant 
reduction in the sample size and the number of CVD events. These limitations must be 
weighed against the unique opportunity to perform an approach using novel models for risk 
assessment of CVD events in a community-based cohort of black adults.
Conclusions
We propose multiple models for CVD risk prediction in black adults. Previous risk 
algorithms were developed in predominantly white populations, and validation in black 
populations has been limited. Our findings using the JHS data in the present study are 
valuable because they confirm that current FHS and ACC/AHA risk algorithms work well in 
black individuals and are not easily improved on. A unique risk calculator for blacks may 
not be necessary.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study Design
Model 1 includes standard cardiovascular disease (CVD) risk factors only. Model 2 includes 
significant standard CVD risk factors plus significant biomarkers selected from a total of 10 
circulation biomarkers representing various pathways. Model 3 includes significant standard 
CVD risk factors plus selected subclinical diseases selected from echocardiographic 
measures and ankle-brachial index (ABI). Model 4 includes significant standard risk factors 
plus ABI only. Model 5 includes significant standard CVD risk factors plus significant 
biomarkers and subclinical disease. Model 6 includes significant standard CVD risk factors 
plus B-type natriuretic peptide (BNP) and ABI. A1c indicates glycated hemoglobin; BP, 
blood pressure; CIMT, carotid intimal-medial thickness; eGFR, estimated glomerular 
filtration rate; HDL; high-density lipoprotein; and JHS, Jackson Health Study.
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Figure 2. Calibration Plots With C Statistics and Distribution of Event Rates in ARIC-Only 
Black Adults and MESA Black Adults
Shown is calibration of the Jackson Heart Study cardiovascular disease (CVD) models 1 and 
6 using external ARIC study (79 events) and MESA (146 events) as samples. Model 1 
includes standard CVD risk factors only. Model 6 includes significant standard CVD risk 
factors plus B-type natriuretic peptide and ankle-brachial index. Intercepts and slopes are 
means (SDs), and C statistics are values (95% CIs). ARIC indicates Atherosclerosis Risk in 
Communities; MESA, Multi-Ethnic Study of Atherosclerosis.
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Table 1
Baseline Characteristics of the Study Sample
Variable
Women
(n = 2390)
Men
(n = 1299)
Sex Pooled
(N = 3689)
Age, mean (SD), y         54 (11)         52 (11)         53 (11)
Body mass index, mean (SD)         32.9 (7.4)         29.9 (6.1)         31.8 (7.1)
BP, mean (SD), mm Hg
 Systolic       125 (18)       128 (17)       126 (18)
 Diastolic         78 (10)         83 (10)         80 (10)
Ratio of fasting total cholesterol to HDL cholesterol           3.9 (1.1)           4.6 (1.5)           4.1 (1.3)
Fasting triglyceride levels, mean (SD), mg/dL       101 (67)       117 (96)       107 (79)
eGFR, mean (SD), mL·min·1.73 m2a         86.0 (16.7)         87.0 (16.0)         86.3 (17.4)
Antihypertensive therapy, No. (%)     1248 (52.2)       514 (39.6)     1762 (47.8)
Statin therapy, No. (%)       228 (9.5)       105 (8.1)       333 (9.0)
Type 2 diabetes mellitus, No. (%)       379 (15.9)       150 (11.5)       529 (14.3)
Current smoking, No. (%)       230 (9.6)       227 (17.5)       457 (12.4)
Follow-up, median (25th to 75th percentiles), y           9.2 (8.4–9.8)           8.9 (8.2–9.7)           9.1 (8.3–9.7)
Total person-years 21 474 11 412 32 886
CVD event rate, No. (95% CI) per 1000 person-years           7.7 (6.6–9.0)           9.1 (7.5–11.0)           8.2 (7.3–9.3)
10-y Risk, mean %
 FRS           9.6           17.9           12.5
 ACC/AHA           5.9           10.5             7.5
Biomarker Level, Median (25th to 75th Percentiles)
Adiponectin, ng/mL     4795 (3136–7072)     3008 (1956–4885)     4081 (2603–6369)
Aldosterone, ng/mL           1.4 (2.4–7.0)           4.8 (3.1–7.4)           4.4 (2.6–7.2)
BNP, pg/mL           7.6 (2.4–16.8)           5.5 (2.2–12.3)           6.6 (2.3–15.1)
Cortisol, μg/dL           8.2 (6.2–10.8)         10.5 (8.1–13.1)           9.0 (6.8–11.9)
C-reactive protein, mg/L           3.6 (1.5–7.3)           1.6 (0.7–3.4)           2.7 (1.1–5.7)
Endothelin 1, pg/mL           1.2 (0.9–1.6)           1.3 (1.0–1.6)           1.2 (1.0–1.6)
A1c,%           5.6 (5.3–6.1)           5.7 (5.3–6.0)           5.6 (5.3–6.1)
HOMA-IR, mass units           3.54 (2.39–5.36)           3.13 (2.19–5.03)           3.42 (2.35–5.30)
Homocysteine, mg/L           0.92 (0.77–1.09)           1.04 (0.90–1.24)           0.96 (0.81–1.15)
Leptin, ng/mL         33.5 (22.7–47.0)           8.1 (4.8–13.7)         23.2 (10.4–39.7)
Subclinical Disease
ABI, median (25th to 75th percentiles)             1.13 (1.06–1.23)           1.17 (1.08–1.26)           1.15 (1.07–1.24)
Upper 10th percentile CIMT, No./total No. (%)                1.77/1452 (12.2)         95/813 (11.7)       272/2265 (12.0)
LV systolic dysfunction, No./total No. (%)           20/1452 (1.4)         27/813 (3.3)         47/2265 (2.1)
LV hypertrophy, No./total No. (%)         102/1452 (7.1)         38/813 (5.0)       140/2265 (6.2)
Abbreviations: ABI, ankle-brachial index; ACC/AHA, American College of Cardiology/American Heart Association Pooled Cohort risk equations; 
A1c, glycated hemoglobin; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BNP, B-type natriuretic 
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peptide; BP, blood pressure; CIMT, carotid intimal-medial thickness; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; 
FRS, Framingham Risk Score; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LV, left ventricular.
SI conversation factors: To convert aldosterone level to picomoles per liter, multiply by 27.74; BNP level to nanograms per liter, multiply by 1.0; 
cortisol level to nanomoles per liter, multiply by 27.588; C-reactive protein level to nanomoles per liter, multiply by 9.524; A1c level to proportion 
of total hemoglobin, multiply by 0.01; homocysteine level to micromoles per liter, multiply by 7.397; and triglyceride levels to millimoles per liter, 
multiply by 0.0113.
a
Estimated using the Chronic Kidney Disease Epidemiology Collaboration equation.
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